Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2010

01.10.2010 | Case Report

AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation

verfasst von: Chanhyok Sakurai-Chin, Yoshifumi Ubara, Tatsuya Suwabe, Junichi Hoshino, Tomoki Yonaha, Eiko Hasegawa, Keiichi Sumida, Rikako Hiramatsu, Masayuki Yamanouchi, Noriko Hayami, Junji Yamauchi, Naoyuki Tominaga, Naoki Sawa, Fumi Takemoto, Kazuhiro Masuoka, Kenmei Takaichi, Kenichi Oohashi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

A 45-year-old Japanese woman had been diagnosed with monoclonal gammopathy of undetermined significance (MGUS) featuring urinary Bence-Jones protein of the lambda type (BJP-lambda) for 11 years. She then developed eyelid purpura, dyspnea, and flank pain. Abdominal CT scans revealed renal infarction. Biopsy of the kidney, heart, jejunum, and skin demonstrated amyloid deposits in the vessel walls, but not in the glomeruli. She was diagnosed as having AL amyloidosis with IgD-lambda monoclonal gammopathy and BJP-lambda. Autologous stem cell transplantation (SCT) was done after chemotherapy with vincristine, daunorubicin, dexamethasone (VAD), and high-dose melphalan (HDM). This reduced the IgD level from 156 to 0.1 mg/dL, along with the disappearance of BJP, despite cerebral infarction during chemotherapy. We recommend SCT for patients with IgD-associated AL amyloidosis.
Literatur
1.
2.
Zurück zum Zitat Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54:271–99. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1975;54:271–99.
3.
Zurück zum Zitat Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transpl. 2001;28:637–42.CrossRef Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transpl. 2001;28:637–42.CrossRef
4.
Zurück zum Zitat Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93.PubMed Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93.PubMed
5.
Zurück zum Zitat Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127:543–51.CrossRefPubMed Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127:543–51.CrossRefPubMed
6.
Zurück zum Zitat Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42:72–7.CrossRefPubMed Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42:72–7.CrossRefPubMed
7.
Zurück zum Zitat Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11:245–56.CrossRefPubMed Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11:245–56.CrossRefPubMed
8.
Zurück zum Zitat Yamazaki O, Ubara Y, Suwabe T, Nakanishi S, Hoshino J, Sawa N, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clin Exp Nephrol. 2009;13:522–5.CrossRefPubMed Yamazaki O, Ubara Y, Suwabe T, Nakanishi S, Hoshino J, Sawa N, et al. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clin Exp Nephrol. 2009;13:522–5.CrossRefPubMed
9.
Zurück zum Zitat Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–93.CrossRefPubMed Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–93.CrossRefPubMed
10.
Zurück zum Zitat Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.CrossRefPubMed Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.CrossRefPubMed
11.
Zurück zum Zitat Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573–89.CrossRefPubMed Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573–89.CrossRefPubMed
12.
Zurück zum Zitat Wang H, Gao C, Xu L, Yang Z, Zhao W, Kong X. Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol. 2008;5:293–8.CrossRefPubMed Wang H, Gao C, Xu L, Yang Z, Zhao W, Kong X. Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol. 2008;5:293–8.CrossRefPubMed
13.
Zurück zum Zitat González García ME, Fernández Alvarez C, Robles Marinas V, González Huerta AJ, Arias Miranda MI, González Rodríguez AP, et al. A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies. Rev Clin Esp. 2008;208:288–94.CrossRefPubMed González García ME, Fernández Alvarez C, Robles Marinas V, González Huerta AJ, Arias Miranda MI, González Rodríguez AP, et al. A series of 618 cases of monoclonal gammopathies of undetermined significance: predictive factors of disappearance of monoclonal component or evolution to malignant gammopathies. Rev Clin Esp. 2008;208:288–94.CrossRefPubMed
14.
Zurück zum Zitat Mseddi-Hdiji S, Haddouk S, Ben Ayed M, Tahri N, Elloumi M, Baklouti S, et al. Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases. Pathol Biol (Paris). 2005;53:19–25. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, Tahri N, Elloumi M, Baklouti S, et al. Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases. Pathol Biol (Paris). 2005;53:19–25.
15.
Zurück zum Zitat O’Connor ML, Rice DT, Buss DH, Muss HB. Immunoglobulin D benign monoclonal gammopathy. A case report. Cancer. 1991;68:611–6.CrossRefPubMed O’Connor ML, Rice DT, Buss DH, Muss HB. Immunoglobulin D benign monoclonal gammopathy. A case report. Cancer. 1991;68:611–6.CrossRefPubMed
16.
Zurück zum Zitat Bladé J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol. 1994;88:395–6.CrossRefPubMed Bladé J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol. 1994;88:395–6.CrossRefPubMed
17.
Zurück zum Zitat Kinoshita T, Nagai H, Murate T, Saito H, Fukatsu T, Hotta T. IgD monoclonal gammopathy of undetermined significance. Int J Hematol. 1997;65:169–72.CrossRefPubMed Kinoshita T, Nagai H, Murate T, Saito H, Fukatsu T, Hotta T. IgD monoclonal gammopathy of undetermined significance. Int J Hematol. 1997;65:169–72.CrossRefPubMed
18.
Zurück zum Zitat Rodon P, Friocourt P, Blanchet S, Levallois D. Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. J Rheumatol. 1996;23:189–90.PubMed Rodon P, Friocourt P, Blanchet S, Levallois D. Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. J Rheumatol. 1996;23:189–90.PubMed
19.
Zurück zum Zitat Kimura S, Iwatsuka R, Aoki T, Odawara J, Asada N, Yamakura M, et al. Primary amyloidosis associated with IgD-lambda M-proteinemia. Rinsho Ketsueki. 2007;48:1555–8.PubMed Kimura S, Iwatsuka R, Aoki T, Odawara J, Asada N, Yamakura M, et al. Primary amyloidosis associated with IgD-lambda M-proteinemia. Rinsho Ketsueki. 2007;48:1555–8.PubMed
20.
Zurück zum Zitat Chong YP, Kim S, Ko OB, Koo JE, Lee D, Park SH, et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci. 2008;23:819–24.CrossRefPubMed Chong YP, Kim S, Ko OB, Koo JE, Lee D, Park SH, et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci. 2008;23:819–24.CrossRefPubMed
21.
Zurück zum Zitat Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.PubMed Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.PubMed
22.
Zurück zum Zitat Saux A, Heroum C, Sportouch C, De Graeve F, Lequellec A, Pagès M. Amyloid cardiomyopathy: a rare cause of cerebral embolism. Rev Neurol (Paris). 2006;162:1128–30. Saux A, Heroum C, Sportouch C, De Graeve F, Lequellec A, Pagès M. Amyloid cardiomyopathy: a rare cause of cerebral embolism. Rev Neurol (Paris). 2006;162:1128–30.
23.
Zurück zum Zitat Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, Vega F. Primary amyloidosis presenting as renal infarction. Eur Radiol. 1996;6:346–8.CrossRefPubMed Arias M, Abreu JA, Iglesias A, Longo J, Lecumberri F, Vega F. Primary amyloidosis presenting as renal infarction. Eur Radiol. 1996;6:346–8.CrossRefPubMed
24.
Zurück zum Zitat Hausfater P, Costedoat-Chalumeau N, Amoura Z, Cacoub P, Papo T, Grateau G, et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol. 2005;34:315–9.CrossRefPubMed Hausfater P, Costedoat-Chalumeau N, Amoura Z, Cacoub P, Papo T, Grateau G, et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol. 2005;34:315–9.CrossRefPubMed
25.
Zurück zum Zitat Adamu B, Alshaebi F, Ahmed M, Beirouti B. Amyloidosis and vascular thrombosis. Saud J Kidney Dis Transpl. 2008;19:137–41. Adamu B, Alshaebi F, Ahmed M, Beirouti B. Amyloidosis and vascular thrombosis. Saud J Kidney Dis Transpl. 2008;19:137–41.
26.
Zurück zum Zitat Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007;69:1136–41.CrossRefPubMed Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007;69:1136–41.CrossRefPubMed
Metadaten
Titel
AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation
verfasst von
Chanhyok Sakurai-Chin
Yoshifumi Ubara
Tatsuya Suwabe
Junichi Hoshino
Tomoki Yonaha
Eiko Hasegawa
Keiichi Sumida
Rikako Hiramatsu
Masayuki Yamanouchi
Noriko Hayami
Junji Yamauchi
Naoyuki Tominaga
Naoki Sawa
Fumi Takemoto
Kazuhiro Masuoka
Kenmei Takaichi
Kenichi Oohashi
Publikationsdatum
01.10.2010
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2010
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0311-2

Weitere Artikel der Ausgabe 5/2010

Clinical and Experimental Nephrology 5/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.